摩蒙塔制药

MNTA NASDAQ
9.60
-0.55
-5.42%
盘后: 9.60 0 0.00% 18:41 07/19 EDT
开盘
10.11
昨收
10.15
最高
10.25
最低
9.60
成交量
49.82万
成交均量(3M)
46.72万
52周最高
32.20
52周最低
9.55
换手率
0.51%
市值
9.47亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供摩蒙塔制药 MNTA股票价格,摩蒙塔制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.
展开 >

最近浏览

名称
价格
涨跌幅